Call me naive, but I genuinely don't see how IMU could be acquired for anything less than US$21B given Gilead's acquisition of Immunomedics for US$21B in Sept. This was for Trodelvy, a breast cancer drug, granted an accelerated approval by the FDA in April.
This valuation overlooks IMU's oncolytic virus products.
DYOR, GLTAH
AGM live chat, page-30
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.004(8.51%) |
Mkt cap ! $319.8M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.3¢ | $2.112M | 47.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 6781697 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.4¢ | 315883 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |